Patients with type 2 DM taking SGLT2 inhibitors as antihyperglycemic drugs are associated with a lower risk of all-cause mortality and arrhythmias compared with those without SGLT2 inhibitors prescription in real-world practice. This evidence concerns the gene SLC5A2 and Arrhythmia.